AUPH - Aurinia Pharma extends gains on following robust Q2 top-line growth
Aurinia Pharmaceuticals (NASDAQ:AUPH) continues its yesterday's post-market rally and is up 14.7% premarket after it reported financial results for Q2 ended June 30, 2021. The company recorded robust revenue growth of 624% to $6.6M over prior quarter, ahead of analyst estimate of $5.14M and much higher than Q2 2020 revenue of $0.03M. AUPH received 415 patient start forms (PSFs) for LUPKYNIS during Q2, +60% Q/Q and over 800 PSFs YTD. The company expects annual net revenue for LUPKYNIS in the range of $40M to $50M for 2021. For Q2, Aurinia recorded a net loss of $47M or $0.37 per share, as compared to a net loss of $26.5M or $0.24 per share in prior year. Aurinia anticipates reporting top-line results from the ongoing AURORA-2 two-year continuation study of voclosporin for the treatment of lupus nephritis by the end of 2021. Net cash used in operating activities increased to $91.5M for H1 2021
For further details see:
Aurinia Pharma extends gains on following robust Q2 top-line growth